Editor's key points † Ropivacaine and its metabolites are excreted by the kidneys. † The pharmacokinetics of ropivacaine is not affected by renal failure. † Metabolites may accumulate in plasma during long-term postoperative infusions; however, non-renal elimination seems to compensate for reduced renal clearance in most patients.
of Helsinki University Central Hospital and the Finnish National Agency for Medicines. Written informed consent was obtained from all study subjects. The subjects were divided into three groups according to their creatinine clearance (CL CR ) values, calculated at the enrolment visit 6 weeks before the study, as follows: Group 1, CL CR .80 ml min
21
(healthy volunteers); Group 2, CL CR 25 -40 ml min 21 ; and Group 3, CL CR ,25 ml min 21 . CL CR values were calculated using the Cockroft -Gault formula. 4 At the enrolment visit, the subjects underwent a thorough physical examination. A 12-lead ECG was taken and laboratory tests included a full blood count, alanine aminotransferase, glutamyltransferase, plasma albumin, human immunodeficiency virus, and hepatitis tests, and also urinary drug screening. A urinary pregnancy test was also performed in female subjects of childbearing potential.
Plasma creatinine was assessed at enrolment using the enzymatic method according to the routine of the clinical laboratory of the hospital. In addition, Jaffé's 5 method was used to obtain a plasma creatinine value on the day of drug administration, which served as the basis for the calculation of CL CR using the Cockroft -Gault formula in the data analysis.
Patients who were already on dialysis or had an arteriovenous shunt in the arm for haemodialysis were not included in the study. Concomitant drug therapy with any potent inhibitor of CYP subenzyme 1A2 (CYP1A2) or 3A4 (CYP3A4) or smoking that could not be discontinued at least 7 days before the planned administration of the study drug was a contraindication for inclusion in the study.
Experiment and follow-up
Before the administration of the experimental drug, the urinary test for pregnancy was repeated in the female subjects and another blood sample was obtained for the determination of CL CR to be used in the statistical analyses. The subjects then received an i.v. infusion of ropivacaine hydrochloride (Naropin w 2 mg ml 21 , AstraZeneca, Sö dertä lje, Sweden) 1 mg kg 21 over 30 min using a volume-controlled infusion pump (B. Braun Perfusor fm, Melsungen, Germany). A low dose and slow infusion rate were chosen to enable a pharmacokinetic assessment with a low risk of inducing systemic toxicity. The subjects were observed by a study physician and two study nurses. Vital signs, ECG, and any side-effects were monitored during the infusion and for at least 30 min thereafter. The study subjects were confined to the study hospital for 36 h, during which time urine was collected and plasma samples taken. The uraemic patients returned to the hospital for blood sampling another three times within the next 2 days. The principal investigator interviewed all subjects by telephone 7-14 days after the administration of ropivacaine.
Blood and urine sampling
Blood samples for the assays of total and unbound concentrations of ropivacaine, a 1 -acid glycoprotein (AAG), which is responsible for plasma binding of local anaesthetics, and total and unbound concentrations of the ropivacaine metabolites 3-OH-ropivacaine and PPX were collected in heparinized vacuum tubes from a cannula in the antecubital vein (of the arm opposite to that used for infusion of ropivacaine) before and 5, 15, 30, 60, and 90 min, and 2, 4, 6, 10, 12, 16, 24, and 36 h after the beginning of the ropivacaine infusion. From the patients, samples were also obtained 48, 60, and 84 h after the infusion of ropivacaine. The blood samples were centrifuged within 1 h and the plasma was transferred to polypropylene tubes which were kept frozen at 2208C until assay. Urine was collected for assays of ropivacaine, 3-OH-ropivacaine, and PPX. The subjects were instructed to empty their bladder (control sample) before the infusion of ropivacaine started, after which urine was collected in 4 h fractions for 24 h followed by one 12 h fraction. Each fraction of urine was weighed and two 5 ml samples were taken from each fraction, transferred to polypropylene tubes and kept frozen at 2208C until assay.
Drug assays
The total plasma concentration of ropivacaine was measured in all plasma samples. The unbound plasma concentration of ropivacaine was determined from a few (three to four) selected samples from each subject as guided by the results from the assays of the total concentrations in order to increase the probability to select plasma samples at times for detectable unbound ropivacaine concentrations. Total PPX was also analysed in plasma as guided by its urinary excretion pattern to increase the probability to select plasma samples at times for detectable concentrations of PPX. The unbound plasma concentration of PPX was analysed in a few (three to four) samples because of its potential contribution to systemic toxicity. The total plasma concentration of ropivacaine was assayed using gas chromatography with a nitrogen-sensitive detector. 6 Liquid -liquid extraction was used for sample preparation. The limit of quantification (LOQ) was 2.7 mg litre 21 as ropivacaine base using 100 ml plasma and the interday coefficient of variation 6.8% (n¼10). The total plasma concentration of unconjugated 3-OH-ropivacaine and PPX was assayed using coupled-column liquid chromatography and mass spectrometric detection with electrospray ionization. The plasma samples were prepared by acidification followed by ultrafiltration. The LOQ was 2.9 mg litre 21 for 3-OH-ropivacaine and 2.3 mg litre 21 for PPX, and the interday coefficient of variation was 7.4% (n¼6) for 3--OH-ropivacaine and 4.3% (n¼10) for PPX. Unbound (free) concentrations of ropivacaine and PPX were assayed in plasma using coupled-column liquid chromatography and mass spectrometry detection, with electrospray ionization after ultrafiltration of the plasma samples. 3 The quantification limit was 2.7 mg litre 21 for ropivacaine and 2.3 mg litre 21 for PPX, with a coefficient of variation of 4.5% (n¼6) for ropivacaine and 4.8% (n¼6) for PPX.
The urinary excretion of ropivacaine, 3-OH-ropivacaine, and PPX was assayed by liquid chromatography and mass spectrometry. 7 Acid hydrolysis and solid-phase extraction were used for sample preparation. 8 The quantification limits were 27, 200, and 70 mg l 21 for ropivacaine, 3-OH-ropivacaine, and PPX, respectively. AAG concentration in plasma was measured using an immunoturbidometric method with a quantification limit of 0.10 g litre 21 . The coefficient of variation was 3.0-5.5% at 0.27 -1.39 g litre 21 (n¼21).
Plasma creatinine concentration, obtained on the day of drug administration, was analysed by Jaffé's 5 method.
Pharmacokinetic analyses
The total (C stop ) and unbound plasma concentrations (C u,stop ) at the end of the infusion were derived directly from the data and the total (C max ) and unbound peak plasma concentrations (C u,max ) and the time to reach the peak plasma concentration (t max ) if this occurred later than the end of infusion. The area under the total plasma concentrationtime curve from zero to infinity (AUC) was calculated using the trapezoidal rule up to the last quantifiable sampling point and addition of the residual area [C last (predicted)/l z ] where l z is the terminal elimination rate constant estimated from the individual linear regression on the terminal part of the log concentration vs time curve. The unbound fractions ( f u ) of ropivacaine and PPX in plasma were calculated by the unbound plasma concentration divided by the total plasma concentration at the time points where both total and unbound concentrations were analysed from the same sample. Owing to the small number of unbound plasma concentrations, the unbound pharmacokinetic variables were estimated using the individual mean values of f u . Unbound AUC (AUC u ) was calculated by the total AUC times the individual mean values of f u . The terminal half-life in plasma (t 1/2 ) was estimated by ln 2/l z .
The fraction of unchanged ropivacaine excreted in urine ( f e ) and the fraction excreted as the major metabolites PPX ( f e , PPX ) and 3-OH-ropivacaine ( f e,3-OH ) were estimated by the cumulative amount excreted in urine/ropivacaine dose. Urine was collected over 36 h. Consequently, during four half-lives of 9 h 9 on average, 94% f e,PPX was expected to be collected in the healthy volunteers. To assess the degree of underestimation of f e,PPX at the end of the urine collection period (t), % recovery (i.e. amount excreted from zero to time t, Ae t /amount excreted from zero to infinity, Ae inf ) was estimated as [12(1/2) n ], where n¼t/t 1/2 . Enumerated values of f e,PPX were calculated by Ae inf /ropivacaine dose.
Statistical analysis
All variables were evaluated by means of descriptive statistics, frequency tables, or graphs as appropriate.
Linear models were used for the exploratory regression analyses modelling the relationship between CL CR and the pharmacokinetic variables. The relationship between the renal function expressed as CL CR and the relevant pharmacokinetic variable estimates, for example, dose-normalized C max and C u,max , dose-normalized AUC and AUC u , and the total plasma clearance (CL) and unbound plasma clearance (CL u ) of ropivacaine and, where possible, of PPX, was calculated.
Three study groups were compared pairwise through the ratio of average pharmacokinetic parameter estimates of ropivacaine and PPX, respectively, for example, AUC, AUC u , C stop , C max, C u,stop , C u,max , CL, and CL u . This was performed after logarithmic transformation of the original pharmacokinetic data and calculation of 95% confidence intervals (CIs) including point estimates, and finally, an antilogarithmic transformation.
The planned number of subjects in this study was estimated to be sufficient to detect pharmacokinetic differences large enough to warrant a change in dose recommendations from a safety point of view. A sample size of 10 in the group with normal renal function and 10 in the group with severe renal impairment would be able to detect a 40% difference in total plasma clearance with 90% power. These calculations were based on a simple two-sided t-test, at a 5% significant level, under normality assumptions, and the assumed values [mean¼400 ml min 21 , standard deviation (SD)¼100 ml min 21 ] for clearance in healthy volunteers were based on Emanuelsson and colleagues. 10 In order to investigate the correlation between the exposure to PPX and renal function, AUC was plotted against CL CR (Fig. 1) . To estimate a possible contribution of non-renal clearance (CL NR ) to the total plasma clearance (CL) of PPX, 1/AUC (proportional to CL) was plotted against renal clearance (CL R ) (Fig. 2) . The equation CL¼CL R +CL NR can be rewritten as 1/AUC¼CL R /dose+CL NR /dose. As a first step, a linear relationship (Y¼bX+a, where b¼1/dose and a¼CL NR /dose) seems reasonable. Dose should be interpreted as a fictitious (mean) dose of PPX, corresponding to PPX formation. CL NR /dose significantly larger than 0 indicates non- renal elimination. A statistical model for the calculation of approximate 95% CIs is described below. When using ordinary least-squares (LS) estimation of the parameters in the common linear regression model
it is assumed that the variable X is observed without error, whereas Y is subject to the error 1. Suppose now that both X and Y are subject to error. Let
The errors 1 and d are assumed to be normally distributed with expected values 0 and SDs s and s d , respectively. The errors are supposed to be uncorrelated. In addition, it is assumed that j and d are uncorrelated as well. Let
denotes the variance of js 2 j . If we estimate b in this model using the ordinary LS estimator b when X is observed with error, we have
where E(b) is the expected value of b, 11 which means that b is underestimated by a factor q 2 /(1+q 2 ), where
An unbiased estimator of b when X is observed with error, but q is known, is thus
where b is the ordinary LS estimator. 
Results
The characteristics of the patients in each study group are given in Tables 1 and 2 . The infusion of ropivacaine was well tolerated by all subjects except one patient in the moderate renal impairment group, in whom the infusion was discontinued after 5 min because of fatigue, nausea, hyperventilation, tachycardia, and hypertension. In this patient, the total plasma concentration of ropivacaine at this point was similar to that of the others.
Ropivacaine
None of the pharmacokinetic parameter estimates of ropivacaine (AUC, AUC u , C stop , C u,stop , CL, CL u , CL R , volume of distribution at steady state V ss , f u , fraction of unbound ropivacaine excreted in urine f e , and terminal half-life t 1/2 ) was related to renal function in terms of creatinine clearance (Tables 3  and 4 ). Three patients in both renal impairment groups had a higher C stop than the healthy volunteers. One of the subjects in the severe renal impairment group had by mistake continued to take diltiazem until 4 days before the ropivacaine dose, and this subject had the slowest decline in the total plasma concentration of ropivacaine. On average, ,1% of the ropivacaine dose was excreted unchanged in the urine in all groups.
3-OH-ropivacaine
The total plasma concentrations of unconjugated 3-OH-ropivacaine were low and similar in the three groups (Fig. 3) , with the exception of one patient in the severe impairment group who had an exceptionally slow decline in plasma Pharmacokinetics of ropivacaine in uraemia BJA concentrations. The fraction of 3-OH-ropivacaine excreted into the urine was lower in the groups with impaired renal function than in the healthy volunteers (Table 4 ) (P,0.001).
Pipecoloxylidide
The total plasma concentrations were low and in general similar between the healthy volunteers and the patients with renal impairment (Table 3 and Fig. 4) than the highest C max of the healthy volunteers. The fraction of PPX excreted in the urine ( f e , PPX ) over 36 h was lower in the moderate and in the severe renal impairment groups than in the healthy volunteers (Table 4) . Renal elimination of PPX was clearly related to renal function. Of the variation in CL R , 81% was accounted for by CL CR (Fig. 5) and for enumerated fraction of PPX excreted ( f e,PPX ) (Fig. 6A ) and cumulative amounts of PPX excreted over 36 h (Fig. 6B ), 29% and 43% of the variation was related to the variation in CL CR . Low correlations were observed between the other pharmacokinetic variables of PPX and CL CR .
Low correlations between the AUC of total PPX and CL CR (R 2 ¼0.061) (Fig. 1) and between AUC and CL R (R 2 ¼0.041) (Fig. 7) suggest that the CL of PPX, in addition to renal excretion of unchanged PPX, also includes non-renal elimination of PPX. On the basis of the model 1/AUC¼CL NR / dose+1/dose×CL R , the adjusted point estimate of CL NR was 6.34 litre h 21 and the lower CI limit was 1.15 litre h 21 (Table 5 ). The point estimate of PPX dose was 3.94 mg. The intercept in the model (CL NR /dose) was significantly larger than 0, which indicates non-renal elimination. Two subjects in the moderate and severe renal impairment groups had outlying and high AUC values for PPX (Fig. 7) and long elimination half-lives (20.3 and 23.6 h). In these patients, non-renal elimination of PPX is less apparent. This is further supported by a higher fraction of ropivacaine excreted as PPX (4.4 -7.5%) (Fig. 6A) and a low expected urinary recovery of PPX (65 -71%) in these subjects. The unbound plasma levels of PPX were low and similar in the different study groups, but the mean fraction of unbound Pharmacokinetics of ropivacaine in uraemia PPX ( f u ) was more than 10 times higher than that of ropivacaine. The contribution of CL NR to the CL of PPX was further supported by a regression analysis of 1/AUC (i.e. CL of PPX) vs CL CR , including the two outliers, which indicated that only 3% (R 2 ¼0.0287) of the variation in 1/AUC was accounted for by variation in CL CR (Fig. 8) .
The subject in the severe renal impairment group (Subject 111, CL CR ¼24 ml min 21 ) who had the highest observed C max of PPX also had the highest unbound concentration (C u,max ) of PPX that was higher than the highest C u.max in the healthy volunteers. In one patient, who had taken diltiazem until 4 days before the ropivacaine exposure, the unbound plasma concentration of PPX was still increasing 12 h after the start of the infusion. In the other subjects, the C u,max of PPX was measured 2 -6 h after the start of the infusion.
There was a weak correlation between the mean AAG plasma concentration and creatinine clearance (R 2 ¼0.14)
( Table 3) . One healthy volunteer and one patient with severe renal impairment had AAG plasma concentrations below and above, respectively, the normal reference range.
Discussion
We found that the baseline creatinine clearance varied between 82 and 122 ml min 21 in the healthy volunteers and between 9 and 41 ml min 21 in the patients. This was considered to be an adequate representation of relevant was initially considered, but was rejected due to the minor effects of renal function on the anticipated pharmacokinetics of ropivacaine and practical difficulties in the enrolment of such subjects. As expected, due to the low f e of ropivacaine, no relationships were found between CL or any of the other pharmacokinetic variables estimated for ropivacaine and renal function in terms of creatinine clearance. 12 On the other hand, the elimination of PPX ( f e,PPX and CL R ) was strongly related to CL CR . However, the correlation between the exposure to PPX Pharmacokinetics of ropivacaine in uraemia (AUC) and creatinine clearance was low, which suggests that the CL of PPX also includes non-renal elimination.
The pharmacokinetics of metabolites is usually obtained after administration of the parent drug but may require separate administration of the metabolite. The latter will require approval for human use by regulatory bodies. To get information on the clearance (CL) of a metabolite, it is generally recognized that it must be given i.v. and separately from the parent drug in order to estimate the dose, that is, total clearance¼dose/AUC. 12 To further evaluate this mechanism in a supplementary analysis, we developed a pharmacokinetic model for nonrenal elimination of a metabolite that to our knowledge has not previously been published. A point estimate and a lower confidence limit of non-renal clearance of a metabolite were estimated by the regression of 1/AUC on renal clearance of the metabolite after administration of the parent drug (ropivacaine) without the need for separate i.v. administration of the metabolite. Using this, we were able to show that the estimated non-renal clearance was larger than zero and statistically significant. The contribution of CL NR to the CL of PPX was further supported by a regression analysis, indicating that only 3% of the variation in 1/AUC (proportional to CL of PPX) was accounted for by variation in CL CR (Fig. 8) .
Fraction of dose excreted as PPX ( f e , PPX ) was probably somewhat underestimated due to, for example, the too short urine collection interval in relation to the t 1/2 of PPX especially in the renal impairment groups. This was reflected by the lower correlation between enumerated fraction of administered dose of ropivacaine excreted as PPX ( f e,PPX ), estimated on the basis of theoretical excretion of PPX to infinity, and creatinine clearance (R 2 ¼0.29) (Fig. 6A) , than between f e,PPX over 36 h and creatinine clearance (R 2 ¼0.43).
The period analysed for PPX plasma concentrations (16 h for the healthy volunteers and 36 h for the patients with renal impairment) possibly resulted in an underestimate of t 1/2 for the healthy volunteers, which may also imply an underestimate of AUC of plasma concentration of PPX for the healthy volunteers. The covariation between the AUC of PPX and creatinine clearance may thus be overestimated in the sense that R 2 is too high (0.061).
Owing to a reduced CL R of PPX in patients with impaired renal function, the PPX exposure in plasma is increased. It is conceivable that this gives an opportunity for increased further hydroxylation of PPX to 3-hydroxy-pipecoloxylidide (3-OH-PPX) and 4-hydroxy-pipecoloxylidide (4-OH-PPX), presumably by CYP1A2 and CYP3A4, respectively. Trace amounts of both metabolites have previously been detected in the urine after a single dose to healthy volunteers. 2 This hypothesis is further supported by a slower rate of formation of PPX than 3--OH-ropivacaine. In pooled human liver microsomes, the apparent Michaelis constant (K m ) value for 3-OH-ropivacaine was 16 mM and for 4-OH-ropivacaine and -PPX about 400 mM. 1 When
Reynolds gave a single i.v. dose of PPX 43 mg to two healthy volunteers, 46% was recovered unchanged in the urine after 24 h, 13 which indicates further metabolism of PPX, but no attempt was made at the time to identify these metabolites. The fraction excreted of 3-OH-ropivacaine was reduced and its half-life increased with a decrease in renal function. A similar increased exposure to unconjugated 3-OH-ropivacaine in plasma could therefore lead to increased possibilities for metabolism to 3-OH-PPX by CYP3A4. One of the two outliers took diltiazem, a CYP3A4 inhibitor, 14 15 up to 4 days before ropivacaine administration. An inhibitory effect of diltiazem on the CYP3A4 metabolism of ropivacaine seems likely, as this subject had the lowest total CL, the highest AUC, the highest f e , and longest half-life of ropivacaine. As CYP3A4 is likely to be involved in a further metabolism of PPX, concomitant treatment with a CYP3A4 inhibitor is also a potential explanation of why this subject showed a high AUC of PPX ( Fig. 7 ) (2.45 h mg litre 21 ).
Non-renal clearance of PPX can to a large extent compensate for the reduction in CL R in renal impairment. The two outliers had an AUC of PPX up to five to six times higher than the other subjects. Assuming that a postoperative continuous epidural infusion of ropivacaine may result in a six-fold higher exposure of unbound PPX plasma concentration in patients with renal impairment, the consequences are reduced as the central nervous systemic toxicity of PPX is significantly less than that of unbound ropivacaine. Furthermore, there is no extra contribution of unbound ropivacaine as it is not affected by renal function.
Our study subjects were not exposed to surgery or major stress and, therefore, their slightly elevated AAG levels in plasma, which is typical for uraemic patients, 16 remained unchanged. In patients undergoing major surgery, on the other hand, there is a stress-induced increase in the acutephase proteins including AAG. 17 Ropivacaine is 94% bound to AAG. As ropivacaine has an intermediate-to-low hepatic extraction ratio, 1 2 its total plasma clearance is expected to vary with changes in the unbound fraction. An increase in AAG results in a decrease in the unbound fraction leading to a decrease in total clearance and an increase in total plasma concentrations during postoperative infusion. On the other hand, the intrinsic (unbound) clearance remains unchanged. 18 19 This is important as it is the unbound plasma concentration of the drug that is related to systemic pharmacodynamic effects and toxicity. The pharmacokinetics of ropivacaine is not altered in patients with impaired renal function. Although unconjugated plasma concentrations of 3-OH-ropivacaine were relatively high (similar to those of PPX), the toxic potential of this metabolite is negligible. Although a substantial part of the active metabolite PPX is renally excreted, there is also clinically relevant non-renal elimination of PPX in patients with impaired renal function. By using a new method, a point estimate and a lower confidence limit of non-renal clearance of the PPX were estimated by the regression of 1/AUC on renal clearance of the metabolite after administration of the mother drug. Owing to inter-individual variation in non-renal clearance, some patients with impaired renal function may show increased exposure to PPX resulting from low non-renal clearance. As these patients also have a relatively longer half-life of PPX, their steady-state plasma concentration during, for example, a postoperative continuous epidural infusion is not expected to be reached until after about 48 h. Furthermore, the clinical consequences are reduced as the central nervous systemic toxicity of PPX is low.
